Skip to main content
NYRADA INC. logo

NYRADA INC. — Investor Relations & Filings

Ticker · NYR ISIN · AU0000070195 ASX Professional, scientific and technical activities
Open in API
Filings indexed 472 across all filing types
Latest filing 2024-11-24 Investor Presentation
Country AU Australia
Listing ASX NYR

About NYRADA INC.

https://www.nyrada.com

Nyrada Inc. specializes in the development of novel small molecule therapeutic agents designed to address unmet needs in cardiovascular health and neuroprotection. The company’s lead programs include a cholesterol-lowering treatment and a neuroprotective treatment for brain injury. The cardiovascular program focuses on an oral PCSK9 inhibitor aimed at managing low-density lipoprotein (LDL) cholesterol levels as an alternative to injectable biologics. The neuroprotection program involves the development of NYR-BI03, a first-in-class small molecule designed to mitigate secondary brain damage following a stroke or traumatic brain injury by targeting canonical transient receptor potential (TRPC) ion channels. These efforts aim to provide effective, accessible pharmacological interventions for both chronic metabolic conditions and acute neurological trauma.

Recent filings

Filing Released Lang Actions
Investor Presentation 20 pages 1.9MB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation November 2024' and contains detailed information about the company's drug development pipeline, market opportunities, clinical trial design, and strategic vision. It includes forward-looking statements, disclaimers, and detailed scientific and market data typical of presentations aimed at investors. There are no financial statements or audit information, nor is it a regulatory filing or announcement of voting results. The length is substantial (15,000 characters), and the content is consistent with an investor presentation rather than a report or announcement. Therefore, the document fits the category of Investor Presentation (IP).
2024-11-24 English
Notification regarding unquoted securities - NYR 6 pages 19.2KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of unquoted securities under an employee incentive scheme. It includes specifics such as the number of securities issued, dates, and mentions key management personnel receiving securities. The document is a formal notification to the ASX about securities issuance, not a financial report or earnings release. It fits the category of announcements regarding new share issues or capital changes. Therefore, it should be classified as a Share Issue/Capital Change (SHA) filing. The document length (6118 characters) and content confirm it is a full notification rather than a brief announcement or a report publication announcement.
2024-11-13 English
Change of Director's Interest Notice - GM 2 pages 6.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director's Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details the change in securities held by a director, including unlisted options granted as part of director remuneration. The content focuses on personal share transactions by a company director, including the number of securities held before and after the change, nature of the change, and contract details related to director services. There is no financial performance data, earnings information, or report publication. This matches the definition of Director's Dealing filings, which report personal share transactions by company directors and executives (insider trades). The document length is 4427 characters, which is consistent with a detailed insider trading notice rather than a full report or announcement. Therefore, the correct classification is DIRS (Director's Dealing).
2024-11-13 English
Nyrada AGM 2024 Chair Address 4 pages 263.2KB
AGM Information Classification · 95% confidence The document is titled 'Nyrada AGM 2024 Chair’s Address' and is dated 12 November 2024. It is a speech given by the acting Chair at the Annual General Meeting (AGM) of Nyrada. The content includes reflections on the company's mission, progress during the financial year, recent achievements, capital raising activities, and thanks to shareholders and the board. There are no detailed financial statements or comprehensive financial performance data typical of an Annual Report or Interim Report. The document is clearly a presentation or address given at the AGM, which fits the definition of AGM Information (AGM-R). The length (8973 characters) is consistent with a detailed AGM address but not a full annual report. Therefore, the document is best classified as AGM Information (AGM-R).
2024-11-11 English
CEO AGM Presentation 13 pages 1.1MB
AGM Information Classification · 100% confidence The document is titled 'AGM Presentation' and includes a detailed presentation by the CEO, dated 12 November 2024, in Sydney, Australia. It contains forward-looking statements, company strategy, drug candidate information, clinical trial design, financial overview, and outlook. The content is structured as a presentation with slides, images (omitted), and detailed business and financial information aimed at investors and shareholders. There is no indication that this is a full annual report, earnings release, or regulatory filing. The document is clearly a presentation given at an Annual General Meeting (AGM), as indicated by the title and content style. Therefore, the appropriate classification is AGM Information (AGM-R).
2024-11-11 English
Nyrada Annual General Meeting Results 4 pages 229.9KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Nyrada Annual General Meeting Results' and dated 12 November 2024. It reports the outcomes of resolutions voted on at the Annual General Meeting (AGM), including which resolutions were passed and which were not. The text includes detailed proxy vote counts and poll results for each resolution. There is no indication of full financial statements or detailed financial performance data, but rather a formal announcement of voting results from the AGM. The document references compliance with ASX Listing Rule 3.13.2 and Corporations Act section 251AA(2), which govern disclosure of voting results. The length of the document (6482 characters) and the content focusing solely on voting outcomes confirm it is not the AGM presentation materials themselves, nor a full annual report or other financial report. Therefore, the document best fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-11-11 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.